Allergy Therapeutics has announced positive interim efficacy biomarker analysis from the first two of four peanut-allergic patient cohorts in the Phase I/IIa clinical trial of VLP Peanut, PROTECT. Analysis from the first two cohorts has shown that treatment with VLP Peanut resulted in a meaningful dose-dependent reduction in skin sensitivity to peanut allergen, with treated patients in cohort 2 showing a 48% reduction in wheal size (the raised, swollen area on the skin that appears after exposur ....
